A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
← catalyst calendarNCT06943872 · readout in 1,138 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →. With German CLL Study Group.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
630estimated
Sites
195
Countries
Argentina, Australia, Austria +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-11 | actual | When the study began enrolling |
| Primary completion | 2029-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
- Drug: Sonrotoclax — also filed as BGB-11417
- Drug: Obinutuzumab — also filed as Gazyva
- Drug: Rituximab — also filed as Rituxan
- Drug: Venetoclax — also filed as Venclexta
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC) for Arm A versus Arm D
measured Up to approximately 51 months
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed